Compare Abbott Laboratories (ABT) vs Tidewater Inc (TDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Tidewater Inc — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Tidewater Inc trades at $72.15 (market cap $3.54B). The key difference: Abbott Laboratories is far larger — about 47.2× Tidewater Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| ABT | TDW | |
|---|---|---|
Market Cap | $166.94B | $3.54B |
Sector | Health | Utilities |
52-Week High | $136.62 | $91.12 |
52-Week Low | $82.57 | $46.32 |
Enterprise Value | $193.69B | $3.64B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Tidewater (TDW) trades at $68.19, up 0.1% on the day, with a mixed technical picture showing bullish overall signals but bearish moving averages. Recent earnings misses in Q1 2026 and Q4 2025 contrast with strong 2025 profitability, including a 22.16% net income margin and 24.03% ROE. The company reported $1.35B revenue in 2025, with net income of $334.66M, though 2026 projections indicate a slight decline. Positive cash flow from operations of $379.11M in 2025 supports financial health, while analyst sentiment remains cautious with a 'Hold' consensus.
Outlook: TDW's valuation appears reasonable with a P/E of 11.5 and EV/EBITDA of 8.52, but recent earnings volatility and a 61.54% analyst hold rating suggest near-term headwinds. Key risks include execution challenges amid declining revenue projections and competitive pressures in offshore marine services. Upside potential hinges on improved earnings consistency and sector recovery, while downside risks involve further profit margin compression and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
